Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis

A. C. Grammer, M. M. Ryals, S. E. Heuer, R. D. Robl, S. Madamanchi, L. S. Davis, B. Lauwerys, M. D. Catalina, P. E. Lipsky

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus erythematosus (SLE). In 2014-2015, the FDA approved 71 new drugs, only one of which targeted a rheumatic disease and none of which was approved for use in SLE. Repositioning/repurposing drugs approved for other diseases using multiple approaches is one possible means to find new treatment options for lupus patients. "Big Data" analysis approaches this challenge from an unbiased standpoint whereas literature mining and crowd sourcing for candidates assessed by the CoLTs (Combined Lupus Treatment Scoring) system provide a hypothesis-based approach to rank potential therapeutic candidates for possible clinical application. Both approaches mitigate risk since the candidates assessed have largely been extensively tested in clinical trials for other indications. The usefulness of a multi-pronged approach to drug repositioning in lupus is highlighted by orthogonal confirmation of hypothesis-based drug repositioning predictions by "Big Data" analysis of differentially expressed genes from lupus patient samples. The goal is to identify novel therapies that have the potential to affect disease processes specifically. Involvement of SLE patients and the scientists that study this disease in thinking about new drugs that may be effective in lupus though crowd-sourcing sites such as LRxL-STAT (www.linkedin.com/in/lrxlstat) is important in stimulating the momentum needed to test these novel drug targets for efficacy in lupus rapidly in small, proof-of-concept trials conducted by LuCIN, the Lupus Clinical Investigators Network (www.linkedin.com/in/lucinstat).

Original languageEnglish (US)
Pages (from-to)1150-1170
Number of pages21
JournalLupus
Volume25
Issue number10
DOIs
StatePublished - Sep 1 2016

Fingerprint

Crowdsourcing
Drug Repositioning
Systemic Lupus Erythematosus
United States Food and Drug Administration
Pharmaceutical Preparations
Therapeutics
Rheumatic Diseases
Research Personnel
Clinical Trials
Genes

Keywords

  • drug repositioning
  • drug repurposing
  • HSCT
  • IL12
  • IL17
  • IL21
  • IL23
  • JAK
  • krill oil
  • LRxL-STAT
  • LuCIN
  • MEDI-7169
  • meditation
  • mindfulness
  • quinacrine
  • ruxolitinib
  • secukinumab
  • Stelara
  • stem cells
  • tofacitinib
  • ustekinumab

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Grammer, A. C., Ryals, M. M., Heuer, S. E., Robl, R. D., Madamanchi, S., Davis, L. S., ... Lipsky, P. E. (2016). Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis. Lupus, 25(10), 1150-1170. https://doi.org/10.1177/0961203316657437

Drug repositioning in SLE : Crowd-sourcing, literature-mining and Big Data analysis. / Grammer, A. C.; Ryals, M. M.; Heuer, S. E.; Robl, R. D.; Madamanchi, S.; Davis, L. S.; Lauwerys, B.; Catalina, M. D.; Lipsky, P. E.

In: Lupus, Vol. 25, No. 10, 01.09.2016, p. 1150-1170.

Research output: Contribution to journalArticle

Grammer, AC, Ryals, MM, Heuer, SE, Robl, RD, Madamanchi, S, Davis, LS, Lauwerys, B, Catalina, MD & Lipsky, PE 2016, 'Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis', Lupus, vol. 25, no. 10, pp. 1150-1170. https://doi.org/10.1177/0961203316657437
Grammer AC, Ryals MM, Heuer SE, Robl RD, Madamanchi S, Davis LS et al. Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis. Lupus. 2016 Sep 1;25(10):1150-1170. https://doi.org/10.1177/0961203316657437
Grammer, A. C. ; Ryals, M. M. ; Heuer, S. E. ; Robl, R. D. ; Madamanchi, S. ; Davis, L. S. ; Lauwerys, B. ; Catalina, M. D. ; Lipsky, P. E. / Drug repositioning in SLE : Crowd-sourcing, literature-mining and Big Data analysis. In: Lupus. 2016 ; Vol. 25, No. 10. pp. 1150-1170.
@article{63e5c8bb3789446c9626c7440bde36da,
title = "Drug repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis",
abstract = "Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus erythematosus (SLE). In 2014-2015, the FDA approved 71 new drugs, only one of which targeted a rheumatic disease and none of which was approved for use in SLE. Repositioning/repurposing drugs approved for other diseases using multiple approaches is one possible means to find new treatment options for lupus patients. {"}Big Data{"} analysis approaches this challenge from an unbiased standpoint whereas literature mining and crowd sourcing for candidates assessed by the CoLTs (Combined Lupus Treatment Scoring) system provide a hypothesis-based approach to rank potential therapeutic candidates for possible clinical application. Both approaches mitigate risk since the candidates assessed have largely been extensively tested in clinical trials for other indications. The usefulness of a multi-pronged approach to drug repositioning in lupus is highlighted by orthogonal confirmation of hypothesis-based drug repositioning predictions by {"}Big Data{"} analysis of differentially expressed genes from lupus patient samples. The goal is to identify novel therapies that have the potential to affect disease processes specifically. Involvement of SLE patients and the scientists that study this disease in thinking about new drugs that may be effective in lupus though crowd-sourcing sites such as LRxL-STAT (www.linkedin.com/in/lrxlstat) is important in stimulating the momentum needed to test these novel drug targets for efficacy in lupus rapidly in small, proof-of-concept trials conducted by LuCIN, the Lupus Clinical Investigators Network (www.linkedin.com/in/lucinstat).",
keywords = "drug repositioning, drug repurposing, HSCT, IL12, IL17, IL21, IL23, JAK, krill oil, LRxL-STAT, LuCIN, MEDI-7169, meditation, mindfulness, quinacrine, ruxolitinib, secukinumab, Stelara, stem cells, tofacitinib, ustekinumab",
author = "Grammer, {A. C.} and Ryals, {M. M.} and Heuer, {S. E.} and Robl, {R. D.} and S. Madamanchi and Davis, {L. S.} and B. Lauwerys and Catalina, {M. D.} and Lipsky, {P. E.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1177/0961203316657437",
language = "English (US)",
volume = "25",
pages = "1150--1170",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - Drug repositioning in SLE

T2 - Crowd-sourcing, literature-mining and Big Data analysis

AU - Grammer, A. C.

AU - Ryals, M. M.

AU - Heuer, S. E.

AU - Robl, R. D.

AU - Madamanchi, S.

AU - Davis, L. S.

AU - Lauwerys, B.

AU - Catalina, M. D.

AU - Lipsky, P. E.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus erythematosus (SLE). In 2014-2015, the FDA approved 71 new drugs, only one of which targeted a rheumatic disease and none of which was approved for use in SLE. Repositioning/repurposing drugs approved for other diseases using multiple approaches is one possible means to find new treatment options for lupus patients. "Big Data" analysis approaches this challenge from an unbiased standpoint whereas literature mining and crowd sourcing for candidates assessed by the CoLTs (Combined Lupus Treatment Scoring) system provide a hypothesis-based approach to rank potential therapeutic candidates for possible clinical application. Both approaches mitigate risk since the candidates assessed have largely been extensively tested in clinical trials for other indications. The usefulness of a multi-pronged approach to drug repositioning in lupus is highlighted by orthogonal confirmation of hypothesis-based drug repositioning predictions by "Big Data" analysis of differentially expressed genes from lupus patient samples. The goal is to identify novel therapies that have the potential to affect disease processes specifically. Involvement of SLE patients and the scientists that study this disease in thinking about new drugs that may be effective in lupus though crowd-sourcing sites such as LRxL-STAT (www.linkedin.com/in/lrxlstat) is important in stimulating the momentum needed to test these novel drug targets for efficacy in lupus rapidly in small, proof-of-concept trials conducted by LuCIN, the Lupus Clinical Investigators Network (www.linkedin.com/in/lucinstat).

AB - Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus erythematosus (SLE). In 2014-2015, the FDA approved 71 new drugs, only one of which targeted a rheumatic disease and none of which was approved for use in SLE. Repositioning/repurposing drugs approved for other diseases using multiple approaches is one possible means to find new treatment options for lupus patients. "Big Data" analysis approaches this challenge from an unbiased standpoint whereas literature mining and crowd sourcing for candidates assessed by the CoLTs (Combined Lupus Treatment Scoring) system provide a hypothesis-based approach to rank potential therapeutic candidates for possible clinical application. Both approaches mitigate risk since the candidates assessed have largely been extensively tested in clinical trials for other indications. The usefulness of a multi-pronged approach to drug repositioning in lupus is highlighted by orthogonal confirmation of hypothesis-based drug repositioning predictions by "Big Data" analysis of differentially expressed genes from lupus patient samples. The goal is to identify novel therapies that have the potential to affect disease processes specifically. Involvement of SLE patients and the scientists that study this disease in thinking about new drugs that may be effective in lupus though crowd-sourcing sites such as LRxL-STAT (www.linkedin.com/in/lrxlstat) is important in stimulating the momentum needed to test these novel drug targets for efficacy in lupus rapidly in small, proof-of-concept trials conducted by LuCIN, the Lupus Clinical Investigators Network (www.linkedin.com/in/lucinstat).

KW - drug repositioning

KW - drug repurposing

KW - HSCT

KW - IL12

KW - IL17

KW - IL21

KW - IL23

KW - JAK

KW - krill oil

KW - LRxL-STAT

KW - LuCIN

KW - MEDI-7169

KW - meditation

KW - mindfulness

KW - quinacrine

KW - ruxolitinib

KW - secukinumab

KW - Stelara

KW - stem cells

KW - tofacitinib

KW - ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84982924154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982924154&partnerID=8YFLogxK

U2 - 10.1177/0961203316657437

DO - 10.1177/0961203316657437

M3 - Article

C2 - 27497259

AN - SCOPUS:84982924154

VL - 25

SP - 1150

EP - 1170

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 10

ER -